Combined deep microRNA and mRNA sequencing identifies protective transcriptomal signature of enhanced PI3Kα signaling in cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 1, 2012, Pages 101-112

  Yang, Kai Chien ^a   Ku, Yuan Chieh ^a   Lovett, Michael ^a   Nerbonne, Jeanne M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac hypertrophy; PI3K ; Transcriptome

Indexed keywords

MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MAPPING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HEART VENTRICLE HYPERTROPHY; HOMEOSTASIS; INNATE IMMUNITY; LIPID METABOLISM; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; BASE SEQUENCE; CARDIOMEGALY; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CLUSTER ANALYSIS; ENDOMYOCARDIAL FIBROSIS; GENE EXPRESSION PROFILING; HEART VENTRICLES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; MALE; MICE; MICE, TRANSGENIC; MICRORNAS; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RNA, MESSENGER; SEQUENCE ANALYSIS, RNA; SIGNAL TRANSDUCTION; TRANSCRIPTOME; VENTRICULAR REMODELING;

EID: 84861993799     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.04.012     Document Type: Article

References (54)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med May 31 1990, 322(22):1561-1566.
2. McMullen J.R., Jennings G.L. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol Apr 2007, 34(4):255-262.
3. McMullen J.R., Shioi T., Zhang L., Tarnavski O., Sherwood M.C., Kang P.M., et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci U S A Oct 14 2003, 100(21):12355-12360.
4. Mende U., Kagen A., Cohen A., Aramburu J., Schoen F.J., Neer E.J. Transient cardiac expression of constitutively active Galphaq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc Natl Acad Sci U S A Nov 10 1998, 95(23):13893-13898.
5. D'Angelo D.D., Sakata Y., Lorenz J.N., Boivin G.P., Walsh R.A., Liggett S.B., et al. Transgenic Galphaq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A Jul 22 1997, 94(15):8121-8126.
6. McMullen J.R., Amirahmadi F., Woodcock E.A., Schinke-Braun M., Bouwman R.D., Hewitt K.A., et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci U S A Jan 9 2007, 104(2):612-617.
7. Yang K.C., Jay P.Y., McMullen J.R., Nerbonne J.M. Enhanced cardiac PI3Kalpha signaling mitigates arrhythmogenic electrical remodeling in pathological hypertrophy and heart failure. Cardiovasc Res Oct 27 2012, 93(2):252-262.
8. Matkovich S.J., Zhang Y., Van Booven D.J., Dorn G.W. Deep mRNA sequencing for in vivo functional analysis of cardiac transcriptional regulators: application to Galphaq. Circ Res May 14 2010, 106(9):1459-1467.
9. Lee J.H., Gao C., Peng G., Greer C., Ren S., Wang Y., et al. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res Oct 27 2011, 9(109):1332-1341.
10. Shioi T., Kang P.M., Douglas P.S., Hampe J., Yballe C.M., Lawitts J., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J Jun 1 2000, 19(11):2537-2548.
11. Zhang S., Weinheimer C., Courtois M., Kovacs A., Zhang C.E., Cheng A.M., et al. The role of the Grb2-p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J Clin Invest Mar 2003, 111(6):833-841.
12. Marionneau C., Brunet S., Flagg T.P., Pilgram T.K., Demolombe S., Nerbonne J.M. Distinct cellular and molecular mechanisms underlie functional remodeling of repolarizing K+ currents with left ventricular hypertrophy. Circ Res Jun 6 2008, 102(11):1406-1415.
13. Yang K.C., Foeger N.C., Marionneau C., Jay P.Y., McMullen J.R., Nerbonne J.M. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy. J Physiol Dec 15 2010, 588(Pt 24):5015-5032.
14. Hackenberg M., Sturm M., Langenberger D., Falcon-Perez J.M., Aransay A.M. miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments. Nucleic Acids Res Jul 2009, 37(Web Server issue):W68-W76.
15. Hackenberg M., Rodriguez-Ezpeleta N., Aransay A.M. miRanalyzer: an update on the detection and analysis of microRNAs in high-throughput sequencing experiments. Nucleic Acids Res Jul 2011, 39(Web Server issue):W132-W138.
16. Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009, 10(3):R25.
17. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol Biol 2006, 342:129-138.
18. Fehniger T.A., Wylie T., Germino E., Leong J.W., Magrini V.J., Koul S., et al. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Res Nov 2010, 20(11):1590-1604.
19. Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., Enright A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res Jan 1 2006, 34(Database issue):D140-D144.
20. Mortazavi A., Williams B.A., McCue K., Schaeffer L., Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods Jul 2008, 5(7):621-628.
21. Reimand J., Kull M., Peterson H., Hansen J., Vilo J. g:Profiler-a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res Jul 2007, 35(Web Server issue):W193-W200.
22. Rao P.K., Kumar R.M., Farkhondeh M., Baskerville S., Lodish H.F. Myogenic factors that regulate expression of muscle-specific microRNAs. Proc Natl Acad Sci U S A Jun 6 2006, 103(23):8721-8726.
23. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell Aug 2008, 15(2):261-271.
24. Rao P.K., Toyama Y., Chiang H.R., Gupta S., Bauer M., Medvid R., et al. Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res Sep 11 2009, 105(6):585-594.
25. Cheng Y., Ji R., Yue J., Yang J., Liu X., Chen H., et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?. Am J Pathol Jun 2007, 170(6):1831-1840.
26. Sayed D., Hong C., Chen I.Y., Lypowy J., Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res Feb 16 2007, 100(3):416-424.
27. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A Nov 28 2006, 103(48):18255-18260.
28. Jentzsch C., Leierseder S., Loyer X., Flohrschutz I., Sassi Y., Hartmann D., et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol Jan 2012, 52(1):13-20.
29. Hoshijima M., Chien K.R. Mixed signals in heart failure: cancer rules. J Clin Invest Apr 2002, 109(7):849-855.
30. Olson E.N., Schneider M.D. Sizing up the heart: development redux in disease. Genes Dev Aug 15 2003, 17(16):1937-1956.
31. O'Neill B.T., Kim J., Wende A.R., Theobald H.A., Tuinei J., Buchanan J., et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab Oct 2007, 6(4):294-306.
32. Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res Apr 29 2011, 108(9):1133-1145.
33. Masiha S., Sundstrom J., Lind L. Inflammatory markers are associated with left ventricular hypertrophy and diastolic dysfunction in a population-based sample of elderly men and women. J Hum Hypertens Jan 12 2012, 10.1038/jhh.2011.113.
34. Valen G. Innate immunity and remodelling. Heart Fail Rev Jan 2011, 16(1):71-78.
35. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med Aug 2 2010, 207(8):1589-1597.
36. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature Dec 18 2008, 456(7224):980-984.
37. Davis B.N., Hilyard A.C., Lagna G., Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature Jul 3 2008, 454(7200):56-61.
38. Cottonham C.L., Kaneko S., Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem Nov 12 2010, 285(46):35293-35302.
39. van Rooij E., Sutherland L.B., Thatcher J.E., DiMaio J.M., Naseem R.H., Marshall W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A Sep 2 2008, 105(35):13027-13032.
40. Thum T., Galuppo P., Wolf C., Fiedler J., Kneitz S., van Laake L.W., et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation Jul 17 2007, 116(3):258-267.
41. van Rooij E. The art of microRNA research. Circ Res Jan 21 2011, 108(2):219-234.
42. Matkovich S.J., Van Booven D.J., Eschenbacher W.H., Dorn G.W. RISC RNA sequencing for context-specific identification of in vivo microRNA targets. Circ Res Jan 7 2011, 108(1):18-26.
43. Lin R.C., Weeks K.L., Gao X.M., Williams R.B., Bernardo B.C., Kiriazis H., et al. PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol Apr 2010, 30(4):724-732.
44. Landgraf P., Rusu M., Sheridan R., Sewer A., Iovino N., Aravin A., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell Jun 29 2007, 129(7):1401-1414.
45. Basso K., Sumazin P., Morozov P., Schneider C., Maute R.L., Kitagawa Y., et al. Identification of the human mature B cell miRNome. Immunity May 2009, 30(5):744-752.
46. Pais H., Moxon S., Dalmay T., Moulton V. Small RNA discovery and characterisation in eukaryotes using high-throughput approaches. Adv Exp Med Biol 2011, 722:239-254.
47. Ambros V. The functions of animal microRNAs. Nature Sep 16 2004, 431(7006):350-355.
48. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature Sep 4 2008, 455(7209):64-71.
49. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature Sep 4 2008, 455(7209):58-63.
50. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature Aug 12 2010, 466(7308):835-840.
51. Kumarswamy R., Volkmann I., Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol Sep 1 2011, 8(5).
52. Tatsuguchi M., Seok H.Y., Callis T.E., Thomson J.M., Chen J.F., Newman M., et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol Jun 2007, 42(6):1137-1141.
53. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res Jun 11 2010, 106(11):1675-1680.
54. Kuwahara F., Kai H., Tokuda K., Kai M., Takeshita A., Egashira K., et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation Jul 2 2002, 106(1):130-135.